Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(8):571; doi:10.1093/jnci/93.8.571
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 8, 571, April 18, 2001
© 2001 Oxford University Press

IN THIS ISSUE

Isotretinoin and Stage I NSCLC

The poor survival rates of patients with stage I non-small-cell lung cancer (NSCLC) following surgical treatment are primarily due to second primary tumors (SPTs) and recurrences. In a phase III randomized trial, Lippman et al. (p. 605) compared NSCLC patients who received the retinoid isotretinoin with those who received placebo to determine the efficacy of this chemopreventive agent in preventing SPTs and recurrences and reducing overall mortality. The authors found no statistically significant differences between the placebo and isotretinoin arms of the study with respect to any of these three end . . . [Full Text of this Article]

Optimizing Intravesical Therapy for Bladder Cancer

Second Cancers in Childhood Cancer Survivors

Lymph Node Staging by Positron Emission Tomography

COX2 and Colon Cancer

Familial Risk of Pancreatic Cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?